Botanix Pharmaceuticals Limited
BXPHF
$0.04
$0.0010.88%
OTC PK
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 5.42M | 5.40M | 1.73M | 1.70M | 123.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 5.42M | 5.40M | 1.73M | 1.70M | 123.00K |
| Cost of Revenue | 1.96M | 1.95M | 820.90K | 803.90K | 393.80K |
| Gross Profit | 3.46M | 3.45M | 912.40K | 893.50K | -270.80K |
| SG&A Expenses | 14.10M | 14.06M | 16.86M | 16.51M | 9.78M |
| Depreciation & Amortization | 389.30K | 388.10K | 367.00K | 359.40K | 364.30K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 16.45M | 16.40M | 18.05M | 17.68M | 10.54M |
| Operating Income | -11.03M | -11.00M | -16.32M | -15.98M | -10.42M |
| Income Before Tax | -10.89M | -10.86M | -17.78M | -17.41M | -10.06M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -10.89M | -10.86M | -17.78M | -17.41M | -10.06M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -10.89M | -10.86M | -17.78M | -17.41M | -10.06M |
| EBIT | -11.03M | -11.00M | -16.32M | -15.98M | -10.42M |
| EBITDA | -10.64M | -10.61M | -15.95M | -15.62M | -10.05M |
| EPS Basic | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| Normalized Basic EPS | 0.00 | 0.00 | -0.01 | -0.01 | 0.00 |
| EPS Diluted | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| Normalized Diluted EPS | 0.00 | 0.00 | -0.01 | -0.01 | 0.00 |
| Average Basic Shares Outstanding | 1.96B | 1.96B | 1.87B | 1.87B | 1.82B |
| Average Diluted Shares Outstanding | 1.96B | 1.96B | 1.87B | 1.87B | 1.82B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |